June 1, 2026

@michaelokun

Parkinson’s disease may not be just one disease protein. Co-pathology means multiple abnormal proteins and disease processes may exist together in the same brain. Matarazzo and colleagues describe in a new paper in Movement Disorders how Parkinson’s disease frequently includes overlapping pathologies such as tau, beta amyloid, TDP-43, vascular disease and inflammation, in addition to alpha-synuclein. Key points: - Most folks w/ Parkinson’s disease appear to have multiple co-existing brain pathologies rather than a pure alpha-synuclein disorder. - Tau, beta amyloid and TDP-43 pathologies were linked to faster progression, cognitive decline and more severe symptoms in many studies. - The review highlights how genetics, inflammation, vascular disease, microbiome changes and immune dysfunction may all interact to shape Parkinson’s progression. My take: This paper is important because it challenges the old idea that Parkinson’s disease is simply a dopamine disorder or just a synuclein disorder. The future of Parkinson’s treatment may require us to target multiple biological pathways simultaneously. We may need to think less about a single culprit and more about an entire ecosystem of interacting disease processes. Here are 5 points that resonated w/ me: 1- Parkinson’s disease is likely more biologically complex than we previously imagined. 2- Co-pathologies may help explain why symptoms and progression differ so dramatically between folks. 3- Tau and beta amyloid pathology may contribute importantly to thinking and memory decline in Parkinson’s disease. 4- Inflammation, vascular disease and immune dysfunction may not just accompany Parkinson’s disease, they may actively shape progression. 5- Precision medicine approaches that combine biomarkers, genetics and pathology may ultimately help us personalize therapies and improve outcomes. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.70324